PLK1 is pivotal, controlling transcription factors to promote proliferation and EMT [50]; its inhibition upregulates PD-L1, stimulating immunity and sensitizing pancreatic cancer to immunotherapy [51], mediates palbociclib resistance in metastatic breast cancer [52], and PLK1 inhibitors combined with abiraterone suppress tumor growth in prostate cancer [53]. The gene discussed is PLK1; the disease is prostate cancer.